Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 154.40

-0.8%

1:46 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	11/18/2006 2:58:20 PM
	of 1834

Neurocrine Biosciences upgraded to "peer perform" Friday, November 17, 2006 3:27:29 AM ET Bear Stearns NEW YORK, November 17 (newratings.com) - Analyst Akhtar Samad of Bear Stearns upgrades Neurocrine Biosciences Inc (NBIX.NAS) from "underperform" to "peer perform." In a research note published yesterday, the analyst mentions that the pressure on the company's stock has been removed, following the identification of a regulatory strategy for Indiplon. Neurocrine Biosciences' current share price reflects the Indiplon delay, the analyst says. Bear Stearns adds, however, that the company's multiple Phase 2 programmes are expected to prevent substantial underperformance from the current levels going forward.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next